User login
Article Type
Changed
Tue, 08/10/2021 - 12:46
Display Headline
MS CONFERENCE NEWS
- Common MS treatment wears off more quickly in Black patients
- A less expensive, more convenient treatment option for MS?
- Investigational drug reduces brain lesions in highly active MS
- Evobrutinib may lower nerve damage biomarker levels
- Disease progression and therapy response vary in MS by ethnicity
- Some MS treatments may heighten COVID risk
- Natalizumab postinfusion reactions
Publications
Sections
- Common MS treatment wears off more quickly in Black patients
- A less expensive, more convenient treatment option for MS?
- Investigational drug reduces brain lesions in highly active MS
- Evobrutinib may lower nerve damage biomarker levels
- Disease progression and therapy response vary in MS by ethnicity
- Some MS treatments may heighten COVID risk
- Natalizumab postinfusion reactions
- Common MS treatment wears off more quickly in Black patients
- A less expensive, more convenient treatment option for MS?
- Investigational drug reduces brain lesions in highly active MS
- Evobrutinib may lower nerve damage biomarker levels
- Disease progression and therapy response vary in MS by ethnicity
- Some MS treatments may heighten COVID risk
- Natalizumab postinfusion reactions
Publications
Publications
Article Type
Display Headline
MS CONFERENCE NEWS
Display Headline
MS CONFERENCE NEWS
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Consolidated Pubs: Do Not Show Source Publication Logo
Use ProPublica
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article